bluebird bio (BLUE) Misses Q1 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
bluebird bio Reports First Quarter 2015 Financial Results and Business Updates
May 6, 2015 4:01 PM EDT-- Achievement of initial enrollment targets in Starbeam and Northstar studies --
-- Presenting HGB-205 beta-thalassemia/sickle cell disease study update at EHA --
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, today reported business highlights and financial results for the first quarter ended March 31, 2015.
We are pleased with the strong start to 2015, especially the faster than expected enrollment for our key adrenoleukodystrophy and... More
